A GLP-1 agonist is a medication that mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1), which your body releases after eating to help regulate blood sugar, slow digestion, and signal fullness to your brain. These drugs were originally developed for type 2 diabetes but are now widely prescribed for weight loss as well. They work by amplifying the effects of that natural hormone, which normally breaks down in your bloodstream within about two minutes.
How GLP-1 Works in Your Body
Every time you eat, your intestines release GLP-1 into your bloodstream. This hormone does three things simultaneously. First, it tells your pancreas to produce more insulin, but only when your blood sugar is elevated. This glucose-dependent mechanism is important because it means GLP-1 doesn’t push blood sugar dangerously low the way some older diabetes medications can. Second, it suppresses glucagon, a hormone that raises blood sugar, during normal and high blood sugar states. Third, it slows down how quickly food leaves your stomach, which blunts the spike in blood sugar and fat levels you’d normally see after a meal.
GLP-1 also acts as a neurotransmitter in the brain. Neurons that produce it project into the hypothalamus, a region packed with GLP-1 receptors that plays a central role in appetite regulation. When those receptors are activated, you feel fuller sooner and stay satisfied longer.
The problem with natural GLP-1 is that it’s destroyed by an enzyme in your blood almost immediately, giving it a half-life of roughly two minutes. That’s far too short to be useful as a medicine. GLP-1 agonist drugs are engineered versions of this hormone with structural tweaks that let them survive much longer in the body.
From Two Minutes to a Full Week
The defining innovation behind GLP-1 agonists is extending that two-minute window into hours or even days. Early versions like exenatide had a half-life of about 2.4 hours, requiring twice-daily injections. Liraglutide stretched that to around 13 hours, making once-daily dosing possible. The newest generation, including semaglutide and tirzepatide, use fatty acid chains that bind to proteins in the blood, slowing their breakdown dramatically. Semaglutide has a half-life of 149 to 161 hours (roughly a week), and tirzepatide sits around 120 hours. This is why both can be taken as a single weekly injection.
Most GLP-1 agonists are given as subcutaneous injections using a prefilled pen, similar to what people use for insulin. In 2019, oral semaglutide became the first pill-form option in the class, taken daily at doses of 7 or 14 mg. The injectable and oral versions lower blood sugar and body weight comparably, though the convenience of a weekly shot versus a daily pill (which must be taken on an empty stomach with minimal water) leads many people to prefer the injection.
Blood Sugar Control in Type 2 Diabetes
GLP-1 agonists lower A1C, the standard measure of average blood sugar over three months, by 1.0% to 2.0% in most clinical trials. That’s a meaningful drop; for someone with an A1C of 8.5%, getting to 7% or below can significantly reduce the risk of diabetes-related complications. Real-world data shows slightly more modest results in some cases. A large retrospective study of over 11,000 patients on liraglutide, dulaglutide, or exenatide found A1C reductions of 0.77% to 1.00% over 12 months. Injectable semaglutide showed the widest range in real-world studies, with reductions from 0.3% to 3.4% depending on the patient population and starting A1C.
Because these drugs only boost insulin when blood sugar is already high, the risk of hypoglycemia (dangerously low blood sugar) is low when used alone. This safety feature comes directly from how the natural hormone works: at normal glucose levels, GLP-1 simply stops stimulating insulin release.
Weight Loss Effects
The appetite-suppressing and stomach-slowing effects of GLP-1 agonists produce substantial weight loss, which led to their approval for obesity treatment independent of diabetes. In the landmark STEP-1 trial, people without diabetes who took semaglutide 2.4 mg (marketed as Wegovy) lost an average of 14.9% of their body weight over 68 weeks. For someone weighing 220 pounds, that translates to roughly 33 pounds.
Tirzepatide, a newer drug that activates both GLP-1 and a related receptor called GIP, pushed those numbers even higher. In the SURMOUNT-1 trial, patients without diabetes lost 15.0%, 19.5%, or 20.9% of their body weight at increasing doses over 72 weeks. These are weight loss figures that previously required bariatric surgery to achieve with medication alone.
Heart Health Benefits
Several large cardiovascular outcome trials have shown that GLP-1 agonists reduce the risk of major cardiovascular events, a composite of heart attack, stroke, and cardiovascular death. Four trials demonstrated reductions of more than 20%. The HARMONY trial showed a 22% reduction, SUSTAIN 6 showed 26%, AMPLITUDE-O showed 27%, and PIONEER showed 21%.
Interestingly, the degree of weight loss doesn’t fully explain these cardiovascular benefits. In the HARMONY trial, the weight difference between the treatment and placebo groups was less than one kilogram, yet the cardiovascular risk reduction was 22%. This suggests GLP-1 agonists protect the heart through mechanisms beyond weight loss alone, possibly by reducing inflammation or improving blood vessel function.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent side effects, which makes sense given that these drugs slow stomach emptying and act on the gut. Nausea is the most common complaint, affecting up to 50% of patients at some point during treatment. Diarrhea is also very common. Vomiting, constipation, abdominal pain, and indigestion occur in 1% to 10% of patients.
These side effects are typically worst during the first few weeks and when the dose is being increased, which is why doctors start at a low dose and titrate up gradually. Most people find the nausea manageable and temporary. In clinical trials of exenatide, only 4% of patients stopped the medication because of nausea. Some formulations cause more GI trouble than others: dulaglutide at its higher dose caused vomiting in 17% of patients compared to 12% for exenatide.
The FDA has placed a boxed warning on GLP-1 agonists related to thyroid cancer risk. In rodent studies, these drugs caused thyroid tumors, specifically medullary thyroid carcinoma. People with a personal or family history of medullary thyroid cancer, or with hereditary conditions linked to it, should not use these medications.
Beyond Diabetes and Obesity
GLP-1 receptors are found throughout the brain, not just in appetite centers, and researchers are actively investigating whether GLP-1 agonists could help with neurodegenerative conditions. Early-stage research is exploring their potential in Alzheimer’s disease, Parkinson’s disease, ALS, multiple sclerosis, Huntington’s disease, traumatic brain injury, stroke recovery, and even psychiatric disorders. The rationale is that GLP-1 receptor activation appears to reduce neuroinflammation and may protect neurons from damage. These investigations are still in relatively early phases, but the breadth of conditions being studied reflects how widely GLP-1 receptors are distributed in the nervous system.